Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake

Nicola Santoro, Mary Savoye, Grace Kim, Katie Marotto, Melissa M Shaw, Bridget Pierpont, Sonia Caprio, Nicola Santoro, Mary Savoye, Grace Kim, Katie Marotto, Melissa M Shaw, Bridget Pierpont, Sonia Caprio

Abstract

Background: A single nucleotide polymorphism (SNP), the rs738409, in the patatin like phospholipase 3 gene (PNPLA3) has been recently associated with increased hepatic steatosis and ALT levels in adults and children. Given the potential role of PNPLA3 in fatty liver development, we aimed to explore whether the influence of PNPLA3 genotype on hepatic fat in obese youth might be modulated by dietary factors such as essential omega polyunsaturated fatty acids (PUFA) intake.

Materials and methods: We studied 127 children and adolescents (56 boys, 71 girls; 58 Caucasians; 30 African Americans and 39 Hispanics; mean age 14.7±3.3; mean BMI 30.7±7.2). The dietary composition was assessed by the Nutrition Data System for Research (NDS-R version 2011). The patients underwent a MRI study to assess the liver fat content (HFF%), ALT measurement and the genotyping of the rs738409 SNP by automatic sequencing.

Results: As previously observed, HFF% and ALT levels varied according to the genotype in each ethnicity. ALT levels and HFF% were significantly influenced by the interaction between genotype and omega-6/omega-3 PUFA ratio (n-6/n-3), p = 0.003 and p = 0.002, respectively. HFF% and ALT levels were, in fact, related to the n-6/n-3 consumption only in subjects homozygote for the G allele of the rs738409 (r2 = 0.45, p = 0.001 and r2 = 0.40, p = 0.006, respectively).

Conclusions: These findings suggest that the association of a high dietary n-6/n-3 PUFA with fatty liver and liver damage in obese youths may be driven by a predisposing genotype.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Interaction between PNPLA3 rs738409 and…
Figure 1. Interaction between PNPLA3 rs738409 and n-6/n-3 PUFA in modulating HFF%.
The figure shows a different degree of regression between HFF% (square root) and n-6/n-3 PUFA (log10) in the three genotypes. In the CC (Panel A) and CG (Panel B) group there was no association between HFF% and n-6/n-3 PUFA (r2 = 0.0004, p = 0.86 and r2 = 0.018, p = 0.39, respectively). Only in the GG group (Panel C) there was a strong association between HFF% and n-6/n-3 PUFA (r2 =  0.45, p = 0.001).
Figure 2. Interaction between PNPLA3 rs738409 and…
Figure 2. Interaction between PNPLA3 rs738409 and n-6/n-3 PUFA in modulating ALT levels.
The figure shows a different degree of regression between ALT (log10) and n-6/n-3 PUFA (log10) in the three genotypes. In the CC (Panel A) and CG (Panel B) group there was no association between ALT and n-6/n-3 PUFA (r2 = 0.0006, p = 0.91 and r2 = 0.015, p = 0.21 respectively). Only in the GG group (Panel C) there was a strong association between HFF% and n-6/n-3 PUFA (r2 =  0.40, p = 0.006).

References

    1. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology. 2009;49:1896–903.
    1. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.
    1. Santoro N, Kursawe R, D'Adamo E, Dykas DJ, Zhang CK, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 2010;52:1281–90.
    1. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1274–80.
    1. Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond). 2010;34:190–4.
    1. Miraglia del Giudice E, Grandone A, Cirillo G, Santoro N, Amato A, et al. The Association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One. 2011;6:e27933.
    1. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–3.
    1. Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010;21:247–52.
    1. Davis JN, Lê KA, Walker RW, Vikman S, Spruijt-Metz D, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010;92:1522–7.
    1. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 28; 2011;286:37085–93.
    1. Perttilä J, Huaman-Samanez C, Caron S, Tanhuanpää K, Staels B, et al. Am J Physiol Endocrinol Metab. In press; 2012. PNPLA3 is Regulated by Glucose in Human Hepatocytes and its I148M Mutant Slows Down Triglyceride Hydrolysis.
    1. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816–23.
    1. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23:46–52.
    1. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, et al. J Hepatol. In Press; 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    1. Molendi-Coste O, Legry V, Leclercq IA. Gastroenterol Res Pract In press; 2011. Why and How Meet n-3 PUFA Dietary Recommendations?
    1. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids Nutr Rev. 2010;68:280–289.
    1. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, et al. Increase in long-chain polyunsaturated fatty acid n – 6/n – 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004;106:635–43.
    1. Xu J, Cho H, O'Malley S, Park JH, Clarke SD. Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. J Nutr. 2002;132:3333–9.
    1. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285–300.
    1. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;5:781–789.
    1. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997;15:287–293.
    1. Kim H, Taksali SE, Dufour S, Befroy D, Goodman TR, et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med. 2008;59:521–527.
    1. Pacifico L, Martino MD, Catalano C, Panebianco V, Bezzi M, et al. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17:3012–9.
    1. Huang Y, He S, Li JZ, Seo YK, Osborne TF, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107:7892–7.
    1. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. 2010;Hepatology.52:1134–42.
    1. Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318–29.
    1. Simopoulos AP. The Importance of the Omega6/Omega3 Fatty Acids Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med. 2008;233:674–688.
    1. He S, McPhaul C, Li JZ, Garuti R, Kinch L, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–15.
    1. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe